Why Exact Sciences is Soaring

Yes, the market is falling today, but that hasn't hurt Exact Sciences ( EXAS ), who received good news about coverage of its colon-cancer test. Barron's Andrew Bary has been writing about Exact Sciences since 2012, when it was still awaiting trial results from its test that is now known as Cologuard. He followed that up in 2014, when the drug was finally approved by the FDA . Exact Sciences gained 75% since that last story, more than double the S&P 500's 35% return, and today it's getting another boost thanks to Aetna's ( AET ) decision to add the drug to a list of covered tests . Cowen's Doug Schenkel and team have the details: